Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-701 vs Lucentis in Wet AMD
NCT04857177Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 3 trial of LucenBS in neovascular age-related macular degeneration (NVAMD), sponsored by Chong Kun Dang Holdings. Started Oct 2018; status: completed.
02
Drugs
LucenBS
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04857177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857177.